Section Arrow
JAGX.NASDAQ
- Jaguar Health Inc
Quotes are at least 15-min delayed:2025/11/16 13:33 EST
Regular Hours
Last
 1.78
+0.08 (+4.71%)
Day High 
1.82 
Prev. Close
1.7 
1-M High
2.4 
Volume 
55.57K 
Bid
1.67
Ask
1.8
Day Low
1.655 
Open
1.67 
1-M Low
1.59 
Market Cap 
6.30M 
Currency USD 
P/E 0.05 
%Yield -- 
10-SMA 1.75 
20-SMA 1.9 
50-SMA
52-W High 33.25 
52-W Low 1.5701 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
37.53/-0.04
Enterprise Value
30.49M
Balance Sheet
Book Value Per Share
1.48
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
9.39M
Operating Revenue Per Share
2.98
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ASBPAspire Biopharma Holdings Inc.0.1063+0.0011+1.05%-- 
CYPHCypherpunk Technologies Inc.2.75+0.99+56.25%-- 
IVVDInvivyd2.35+0.58+32.77%-- 
APLTApplied Therapeutics0.2183-0.0517-19.15%-- 
RXRXRecursion Pharmaceuticals4.14-0.19-4.39%-- 
Quotes are at least 15-min delayed:2025/11/16 13:33 EST
Industry overview quotes are at least 15 minutes delayed
Business Description
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.